FDA votes against lumbar spinal stenosis device
This article was originally published in Clinica
St Francis Medical Technologies' novel device for treating the debilitating degenerative spinal condition, lumbar spinal stenosis (LSS), is not ready for marketing in the US, an FDA advisory panel has concluded.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.